Latest Breakthrough
Oncology Research News

Adding anti-PD-1 immunotherapy prior to surgery fundamentally increases pathologic complete response (pCR) and significantly reduces long-term recurrence rates in high-risk early TNBC.

T-DXd (Enhertu) breaks the traditional binary classification of HER2-positive vs HER2-negative, opening targeted antibody-drug conjugate (ADC) therapy to over 50% of metastatic breast cancer patients previously deemed HER2-negative.

Adjuvant 3-year Osimertinib after surgery provides an unprecedented survival halo in Stage IB-IIIA EGFR-mutated lung cancer. Amivantamab + Lazertinib adds a new first-line chemo-free benchmark in advanced disease.

Combining KRAS G12C inhibitors (Sotorasib or Adagrasib) with anti-EGFR antibodies (Cetuximab) successfully overcomes historical bypass resistance mechanisms in metastatic colorectal cancer.

ESR1 mutations emerge in up to 40% of patients following aromatase inhibitor + CDK4/6 inhibitor therapy. Elacestrant is the first approved oral selective estrogen receptor degrader tailored for this resistant subgroup.

The EV-302 regimen represents the single biggest survival advancement in advanced urothelial carcinoma in over 40 years, nearly doubling median overall survival compared to standard chemotherapy.

Radioligand therapy combines a targeting molecule that binds to Prostate-Specific Membrane Antigen (PSMA) with a radioactive beta emitter (Lu-177), delivering localized radiation directly to prostate cancer cells throughout the body.

Integrating immune checkpoint inhibition directly into definitive chemoradiotherapy (cisplatin + external beam radiation + brachytherapy) significantly improves progression-free survival in FIGO Stage IB2-VIII2 cervical cancer.

Giving 3-4 cycles of Nivolumab or Durvalumab with chemotherapy prior to surgery, followed by post-operative immunotherapy maintenance, achieves unprecedented event-free survival in Stage II-III resectable lung cancer.

Dr. Narendra Rathore’s core specialization focus: Adding anti-PD-L1 (Durvalumab) or anti-PD-1 (Pembrolizumab) to standard Gemcitabine + Cisplatin establishes the first new first-line survival landmark in advanced gallbladder and bile duct cancers in over a decade.

Claudin 18.2 (CLDN18.2) is a tight junction protein expressed in approximately 38% of gastric cancers. Zolbetuximab represents the first-in-class targeted monoclonal antibody tailored for CLDN18.2+/HER2- gastric adenocarcinomas.

Frontline maintenance with Olaparib + Bevacizumab or Niraparib monotherapy in BRCA-mutated or Homologous Recombination Deficient (HRD-positive) advanced ovarian cancer yields long-term, durable remissions exceeding 5 years.

Lifileucel is the first FDA & ESMO approved cellular therapy for solid tumors. Immune T-cells are harvested directly from a patient's resected tumor, expanded into billions of tumor-specific cells in a specialized lab, and re-infused.

The SWOG S1826 trial demonstrated that replacing Bleomycin or Brentuximab with Nivolumab (N-AVD) in Stage III/IV Hodgkin Lymphoma produces superior progression-free survival with significantly lower toxicity.

Belzutifan represents a brand-new class of targeted therapy that directly inhibits Hypoxia-Inducible Factor 2-alpha (HIF-2α), reversing the pseudohypoxic vascular drive inherent in VHL-mutated or clear cell kidney cancers.

HPV-associated oropharyngeal squamous cell carcinoma has a significantly superior prognosis. ASCO guidelines support de-escalated radiation doses (60 Gy vs 70 Gy) or substituting cisplatin with carboplatin/cetuximab to preserve long-term swallowing and speech function.

A single priming dose of anti-CTLA-4 (Tremelimumab) combined with regular anti-PD-L1 (Durvalumab) establishes a durable survival plateau in unresectable hepatocellular carcinoma without increasing bleeding risk.

Targeted combination therapies targeting IDH1 mutations (Ivosidenib) or KMT2A/NPM1 rearrangements (Menin inhibitors like Revumenib) deliver remarkable complete remissions in intensive chemo-ineligible AML.

Replacing conventional FOLFIRINOX with NALIRIFOX (liposomal irinotecan + 5-FU/leucovorin + oxaliplatin) significantly improves overall survival and progression-free survival as first-line therapy in metastatic pancreatic cancer.

Fruquintinib is an oral potent, highly selective inhibitor of VEGF receptors 1, 2, and 3. It provides a clean, well-tolerated oral treatment option for heavily pretreated metastatic colorectal cancer regardless of RAS/BRAF mutation status.